EATON VANCE NAT.MUN.OPP. Logo
US27829L1052

EATON VANCE NAT.MUN.OPP.

Ins Portfolio
Kostengünstig und breit gestreut in Europa investieren. Jetzt entdecken
Anzeige

Kurse werden geladen...

Prognose

Für dieses Unternehmen liegen uns keine Analysten-Daten vor.

Scoring-Modelle

Dividenden-Strategie5 / 15
HGI-Strategie11 / 18
Levermann-Strategie-6 / 13
Powered byaktien.guide

News


  • Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI

    As previously reported, 15 out of 16 (94%) patients in Phase 2b in the Per Protocol Population experienced Clinical Cure (CC) and all 15 of 15 (100%) remained free of C. difficile infection (CDI) recurrence through one month after EOT In contrast, 2 of 14 (14%) patients treated with the standard of care, oral vancomycin, experienced recurrent infection within one month after EOT When Phase 2b results are combined with Phase 2a results, 25 of 25 (100%) ibezapolstat-treated patients with CDI who had CC at EOT remained recurrence-free through 1 month after EOT; additionally, all 5 Phase 2b ibezapolstat-treated patients observed for up to 3 months following CC experienced no recurrence of infection Adding to this Lancet Microbe publication, two recent Journal of Antimicrobial Agents and Chemotherapeutics publications regarding, respectively, favorable gut microbiome effects which differentiate IBZ from other anti-CDI antibiotics and positive results from an in-silico study predicting the microbiome-restorative potential of IBZ The totality of ibezapolstat data-to-date further advances Acurx's robust data package and are reshaping the therapeutic landscape for future treatment of CDI with ibezapolstat's innovative and potentially transformative new class of antibiotics to treat gram-positive infections while preserving and restoring the protective gut microbiota Acurx is well positioned to begin international Phase 3 clinical trials and has previously been granted FDA QIDP and Fast-Track Designation and has received SME (Small and Medium-sized Enterprise) designation by the EMA STATEN ISLAND, N.Y.» Mehr auf prnewswire.com


  • Distribution Dates and Amounts Announced for Eaton Vance Closed-End Funds

    BOSTON--(BUSINESS WIRE)--The following Eaton Vance closed-end funds (the “Funds”) announced distributions today as detailed below. Declaration – 2/3/2025 Ex-Date – 2/13/2025 Record – 2/13/2025 Payable – 2/24/2025 Municipal Bond Funds:   Fund Ticker Distribution Change From Prior Distribution Closing Market Price – 1/31/25 Distribution Rate at Market Price Eaton Vance California Municipal Income Trust CEV $0.0500 - $10.14 5.92% Eaton Vance Municipal Income Trust EVN $0.0513 - $10.31 5.97% Taxabl.» Mehr auf businesswire.com


  • Distribution Dates and Amounts Announced for Eaton Vance Closed-End Funds

    BOSTON--(BUSINESS WIRE)--The following Eaton Vance closed-end funds (the “Funds”) announced distributions today as detailed below. Declaration – 1/2/2025 Ex-Date – 1/13/2025 Record – 1/13/2025 Payable – 1/22/2025 Municipal Bond Funds: Fund Ticker Distribution Change From Prior Distribution Closing Market Price – 12/31/24 Distribution Rate at Market Price Eaton Vance California Municipal Income Trust CEV $0.0500 - $10.04 5.98% Eaton Vance Municipal Income Trust EVN $0.0513 - $10.11 6.09% Taxable.» Mehr auf businesswire.com

Dividenden

Alle Kennzahlen
In 2025 hat EATON VANCE NAT.MUN.OPP. bereits +0,44 Dividende ausgeschüttet. Die letzte Dividende wurde im Juni gezahlt.

Unternehmenszahlen

Im letzten Quartal hatte EATON VANCE NAT.MUN.OPP. einen Umsatz von +7,03 Mio und ein Nettoeinkommen von +11,36 Mio
(EUR)Sep. 2024
YOY
Umsatz+7,03 Mio-
Bruttoeinkommen+5,33 Mio-
Nettoeinkommen+11,36 Mio-
EBITDA+11,36 Mio-

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+218,02 Mio
Anzahl Aktien
15,62 Mio
52 Wochen-Hoch/Tief
+15,48 - +13,12
Dividendenrendite
+5,86%
Dividenden TTM
+0,82
Nächste Dividende
+0,0582
Beta
0,37
KGV (PE Ratio)
+9,06
KGWV (PEG Ratio)
0,09
KBV (PB Ratio)
+0,87
KUV (PS Ratio)
+18,26

Unternehmensprofil

Eaton Vance National Municipal Opportunities Trust ist ein geschlossener, festverzinslicher Investmentfonds, der von Eaton Vance Management aufgelegt und verwaltet wird. Der Fonds investiert in die festverzinslichen Märkte der Vereinigten Staaten. Er investiert sein Vermögen hauptsächlich in kommunale Schuldverschreibungen. Der Fonds führt internes Research durch, um seine Investitionen zu tätigen. Der Eaton Vance National Municipal Opportunities Trust wurde am 29. Mai 2009 aufgelegt und hat seinen Sitz in den Vereinigten Staaten.

Name
EATON VANCE NAT.MUN.OPP.
CEO
Payson F. Swaffield CFA
SitzBoston, ma
USA
Website
Börsengang
Mitarbeiter0

Ticker Symbole

BörseSymbol
NYSE
EOT
🍪

Parqet nutzt Cookies.Erfahre Mehr